About

Herald Therapeutics is a clinical-stage biotechnology company developing innovative therapies for life-threatening pulmonary and cardiac diseases.

We are dedicated to improving patients’ lives by developing therapies that restore normal lung and heart function.

Acute Respiratory Distress Syndrome (ARDS) patients suffer from a severe lung deficiency of T3, a naturally occurring thyroid hormone that helps the lung function effectively and recover from injury. Replenishing lung T3 addresses multiple drivers of lung pathology simultaneously, including edema resorption, inflammation and injury recovery, surfactant synthesis, cytoprotection, and fibrosis prevention. Learn more about the science that supports our purpose.